-
Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874.
Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. PMID: 28078110.
View in:
PubMed Mentions:
-
Abstract No. 437 Radioembolization with 490Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. Journal of Vascular and Interventional Radiology. 2015 Feb 1; 26(2):s191.
N. Fidelman, R.K. Kerlan, A.G. Taylor, K. Kolli, M. Kohi, R. Hawkins, M. Pampaloni, C. Atreya, E.K. Bergsland, R.K. Kelley, A. Ko, W.M. Korn, K. Van Loon, J. Luan, R.M. McWhirter, C. Johanson, A. Venook. .
View in:
Publisher Site Mentions:
-
90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80.
Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. PMID: 24448917.
View in:
PubMed Mentions:
2 Fields:
Translation:
HumansCTClinical Trials
-
Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC). Journal of Clinical Oncology. 2013 May 20; 31(15_suppl):3507-3507.
Ryan Bruce Corcoran, Gerald Steven Falchook, Jeffrey R. Infante, Omid Hamid, Wells A. Messersmith, Adil Daud, Eunice Lee Kwak, David P. Ryan, Razelle Kurzrock, Chloe Evelyn Atreya, Jennifer Luan, Peng Sun, Megan Schaeffer, Monica Motwani, Maureen R Bleam, Christopher H Moy, Kiran Patel, Keith W. Orford, Scott Kopetz, Alan Paul Venook. .
View in:
Publisher Site Mentions:
-
Association of pyrexia and durable response in advanced melanoma patients treated with the combination of dabrafenib and trametinib. Journal of Clinical Oncology. 2012 May 20; 30(15_suppl):e19046-e19046.
Edward Cha, Andrea Kantor, Alain Patrick Algazi, Jimmy Hwang, Jennifer Luan, Alan Paul Venook, Leslie Ziani, Shonda M Little, Kiran Patel, Adil Daud. .
View in:
Publisher Site Mentions:
-
BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212). Journal of Clinical Oncology. 2012 May 20; 30(15_suppl):3528-3528.
Ryan Bruce Corcoran, Gerald Steven Falchook, Jeffrey R. Infante, Omid Hamid, Wells A. Messersmith, Eunice Lee Kwak, David P. Ryan, Razelle Kurzrock, Adrienne A Brenner, Jennifer Luan, Peng Sun, Alicia J Allred, Shonda M Little, Kiran Patel, Scott Kopetz, Alan Paul Venook. .
View in:
Publisher Site Mentions:
-
Self-assessed sleep quality in chronic kidney disease. Int Urol Nephrol. 2005; 37(1):159-65.
Kurella M, Luan J, Lash JP, Chertow GM. PMID: 16132780.
View in:
PubMed Mentions:
14 Fields:
Translation:
Humans
-
Validation of the Kidney Disease Quality of Life (KDQOL) cognitive function subscale. Kidney Int. 2004 Dec; 66(6):2361-7.
Kurella M, Luan J, Yaffe K, Chertow GM. PMID: 15569327.
View in:
PubMed Mentions:
28 Fields:
Translation:
Humans
-
Cognitive impairment in chronic kidney disease. J Am Geriatr Soc. 2004 Nov; 52(11):1863-9.
Kurella M, Chertow GM, Luan J, Yaffe K. PMID: 15507063.
View in:
PubMed Mentions:
135 Fields:
Translation:
Humans